Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Shares Purchased by Bank Julius Baer & Co. Ltd Zurich

Bank Julius Baer & Co. Ltd Zurich increased its holdings in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) by 28.2% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 40,924 shares of the biopharmaceutical company’s stock after purchasing an additional 9,011 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich’s holdings in Inovio Pharmaceuticals were worth $475,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Vanguard Group Inc. increased its position in Inovio Pharmaceuticals by 71.3% during the 2nd quarter. Vanguard Group Inc. now owns 9,585,288 shares of the biopharmaceutical company’s stock worth $258,323,000 after purchasing an additional 3,991,177 shares in the last quarter. Coatue Management LLC acquired a new stake in Inovio Pharmaceuticals during the 2nd quarter worth approximately $74,113,000. State Street Corp increased its position in Inovio Pharmaceuticals by 9.5% during the 1st quarter. State Street Corp now owns 1,735,565 shares of the biopharmaceutical company’s stock worth $12,913,000 after purchasing an additional 150,421 shares in the last quarter. Nuveen Asset Management LLC increased its position in Inovio Pharmaceuticals by 95.3% during the 2nd quarter. Nuveen Asset Management LLC now owns 1,085,239 shares of the biopharmaceutical company’s stock worth $29,247,000 after purchasing an additional 529,562 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in Inovio Pharmaceuticals by 27.5% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 979,197 shares of the biopharmaceutical company’s stock worth $26,390,000 after purchasing an additional 211,383 shares in the last quarter. 33.78% of the stock is owned by hedge funds and other institutional investors.

Several brokerages have issued reports on INO. Stifel Nicolaus lowered their price objective on shares of Inovio Pharmaceuticals from $24.00 to $16.00 in a research report on Tuesday, August 11th. Maxim Group raised shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research report on Monday, September 28th. HC Wainwright reaffirmed a “hold” rating on shares of Inovio Pharmaceuticals in a research report on Wednesday, September 9th. ValuEngine downgraded shares of Inovio Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, November 10th. Finally, Cantor Fitzgerald downgraded shares of Inovio Pharmaceuticals from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $31.00 to $12.00 in a research report on Monday, September 28th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the company’s stock. Inovio Pharmaceuticals currently has an average rating of “Hold” and an average target price of $12.00.

INO stock opened at $10.54 on Friday. Inovio Pharmaceuticals, Inc. has a twelve month low of $2.28 and a twelve month high of $33.79. The company has a current ratio of 10.06, a quick ratio of 10.06 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $1.79 billion, a P/E ratio of -6.13 and a beta of 1.08. The firm has a 50 day simple moving average of $11.27 and a 200-day simple moving average of $15.19.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings results on Monday, November 9th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.30. Inovio Pharmaceuticals had a negative net margin of 8,099.02% and a negative return on equity of 120.41%. The business had revenue of $0.24 million during the quarter, compared to the consensus estimate of $3.05 million. During the same quarter last year, the company earned ($0.25) earnings per share. The business’s quarterly revenue was down 72.7% compared to the same quarter last year. On average, research analysts predict that Inovio Pharmaceuticals, Inc. will post -0.87 EPS for the current year.

Inovio Pharmaceuticals Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells and facilitate cross-strain protection against unmatched and matched pathogens.

Read More: Cash Flow Analysis in Stock Selection

Want to see what other hedge funds are holding INO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inovio Pharmaceuticals, Inc. (NASDAQ:INO).

Institutional Ownership by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.